BRPI0610089A2 - intensificador de resistÊncia À insulina - Google Patents
intensificador de resistÊncia À insulinaInfo
- Publication number
- BRPI0610089A2 BRPI0610089A2 BRPI0610089-9A BRPI0610089A BRPI0610089A2 BR PI0610089 A2 BRPI0610089 A2 BR PI0610089A2 BR PI0610089 A BRPI0610089 A BR PI0610089A BR PI0610089 A2 BRPI0610089 A2 BR PI0610089A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor agonist
- glp
- insulin resistance
- dosage regimen
- endogenous
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 4
- 239000003623 enhancer Substances 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 6
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 6
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002060 circadian Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTENSIFICADOR DE RESISTÊNCIA À INSULINA. A presente invenção refere-se a um novo regime de dosagem de agonistas de receptor de GLP-1 que causa pouco ou nenhum efeito colateral ou interações de fármacos, e é apropriado para aperfeiçoar a resistência à insulina. Além disso, é fornecido um intensificador de resistência à insulina para uso no regime de dosagem. O regime de dosagem compreende administrar repetidamente, de preferência de uma maneira não invasiva, um agonista de receptor de GLP-1 pelo menos antes de comer, por um período de tempo predeterminado, para criar uma condição similar a que é observada com a secreção temporária pós-prandial do agonista de receptor de GLP-1 endógeno, em vez de administrá-lo continuamente. Isto cria uma variação similar ou ampliada nos níveis de plasma do agonista de receptor de GLP-1, quando comparado com a variação circadiana do agonista de receptor de GLP-1 endógeno em um indivíduo sadio. É fornecida também uma composição farmacêutica para uso em um regime de dosagem contendo agonista de receptor de GLP-1 como um ingrediente ativo
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005155312 | 2005-05-27 | ||
| PCT/JP2006/310590 WO2006126688A1 (ja) | 2005-05-27 | 2006-05-26 | インスリン抵抗性改善剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0610089A2 true BRPI0610089A2 (pt) | 2008-12-09 |
Family
ID=37452110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0610089-9A BRPI0610089A2 (pt) | 2005-05-27 | 2006-05-26 | intensificador de resistÊncia À insulina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090233851A1 (pt) |
| EP (1) | EP1886692A4 (pt) |
| JP (1) | JPWO2006126688A1 (pt) |
| KR (1) | KR20080011675A (pt) |
| CN (1) | CN101184509A (pt) |
| AU (1) | AU2006250347A1 (pt) |
| BR (1) | BRPI0610089A2 (pt) |
| CA (1) | CA2606902A1 (pt) |
| IL (1) | IL187230A0 (pt) |
| RU (1) | RU2007149288A (pt) |
| WO (1) | WO2006126688A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351262A1 (en) * | 2016-12-30 | 2018-07-25 | Istanbul Universitesi Rektorlugu | Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| MXPA00012286A (es) * | 1998-06-12 | 2002-10-17 | Bionebraska Inc | Peptide-1 similar a glucagon mejora la respuesta celular beta a glucosa en sujetos con tolerancia danada de glucosa. |
| WO2001051071A2 (en) * | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| EP1949908A1 (en) * | 2001-03-07 | 2008-07-30 | Novo Nordisk A/S | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| KR20040058324A (ko) * | 2001-11-26 | 2004-07-03 | 다이이찌 산토리 파마 가부시키가이샤 | 경비흡수용 의약 조성물 |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| JPWO2004037859A1 (ja) * | 2002-10-11 | 2006-02-23 | 株式会社三和化学研究所 | Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤 |
| US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
-
2006
- 2006-05-26 BR BRPI0610089-9A patent/BRPI0610089A2/pt not_active Application Discontinuation
- 2006-05-26 CN CNA2006800185815A patent/CN101184509A/zh active Pending
- 2006-05-26 JP JP2007517925A patent/JPWO2006126688A1/ja active Pending
- 2006-05-26 AU AU2006250347A patent/AU2006250347A1/en not_active Abandoned
- 2006-05-26 US US11/921,027 patent/US20090233851A1/en not_active Abandoned
- 2006-05-26 CA CA002606902A patent/CA2606902A1/en not_active Abandoned
- 2006-05-26 KR KR1020077027631A patent/KR20080011675A/ko not_active Withdrawn
- 2006-05-26 RU RU2007149288/15A patent/RU2007149288A/ru not_active Application Discontinuation
- 2006-05-26 EP EP06746919A patent/EP1886692A4/en not_active Withdrawn
- 2006-05-26 WO PCT/JP2006/310590 patent/WO2006126688A1/ja not_active Ceased
-
2007
- 2007-11-08 IL IL187230A patent/IL187230A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080011675A (ko) | 2008-02-05 |
| WO2006126688A1 (ja) | 2006-11-30 |
| EP1886692A1 (en) | 2008-02-13 |
| AU2006250347A1 (en) | 2006-11-30 |
| JPWO2006126688A1 (ja) | 2008-12-25 |
| US20090233851A1 (en) | 2009-09-17 |
| IL187230A0 (en) | 2008-02-09 |
| RU2007149288A (ru) | 2009-07-10 |
| EP1886692A4 (en) | 2009-09-30 |
| CN101184509A (zh) | 2008-05-21 |
| CA2606902A1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molero et al. | Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review | |
| Luckenbaugh et al. | Do the dissociative side effects of ketamine mediate its antidepressant effects? | |
| Huss et al. | Influence of pain and analgesia on orthopedic and wound-healing models in rats and mice | |
| CY1109578T1 (el) | Μηχανισμος εμφανισης δοσολογιας για μια συσκευη χορηγησης φαρμακου | |
| ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
| CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
| CL2021001609A1 (es) | Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| BRPI0719009B8 (pt) | mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| MX2007009960A (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| ATE439123T1 (de) | Verwendung von emulsionen zur intra- und periocularen injection | |
| ATE413162T1 (de) | Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln | |
| NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
| WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
| BRPI0418373A (pt) | composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| PE20040973A1 (es) | Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales | |
| BRPI0514043A (pt) | medicamentos para tratar doença respiratória crÈnica | |
| BRPI0519656A2 (pt) | terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida | |
| ATE361065T1 (de) | Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes | |
| BR112022004535A2 (pt) | Formulações de entrega de fármaco | |
| BRPI0610089A2 (pt) | intensificador de resistÊncia À insulina | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| BRPI0418801A (pt) | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |